| Literature DB >> 17611618 |
Shonna M McBride1, Vincent A Fischetti, Donald J Leblanc, Robert C Moellering, Michael S Gilmore.
Abstract
Enterococcus faecalis, a ubiquitous member of mammalian gastrointestinal flora, is a leading cause of nosocomial infections and a growing public health concern. The enterococci responsible for these infections are often resistant to multiple antibiotics and have become notorious for their ability to acquire and disseminate antibiotic resistances. In the current study, we examined genetic relationships among 106 strains of E. faecalis isolated over the past 100 years, including strains identified for their diversity and used historically for serotyping, strains that have been adapted for laboratory use, and isolates from previously described E. faecalis infection outbreaks. This collection also includes isolates first characterized as having novel plasmids, virulence traits, antibiotic resistances, and pathogenicity island (PAI) components. We evaluated variation in factors contributing to pathogenicity, including toxin production, antibiotic resistance, polymorphism in the capsule (cps) operon, pathogenicity island (PAI) gene content, and other accessory factors. This information was correlated with multi-locus sequence typing (MLST) data, which was used to define genetic lineages. Our findings show that virulence and antibiotic resistance traits can be found within many diverse lineages of E. faecalis. However, lineages have emerged that have caused infection outbreaks globally, in which several new antibiotic resistances have entered the species, and in which virulence traits have converged. Comparing genomic hybridization profiles, using a microarray, of strains identified by MLST as spanning the diversity of the species, allowed us to identify the core E. faecalis genome as consisting of an estimated 2057 unique genes.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17611618 PMCID: PMC1899230 DOI: 10.1371/journal.pone.0000582
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Bacterial strains used in this study
| Strain | Isolation date | Source | MLST | Synonyms and Description | References |
| T1 | ≤1950 | unknown |
| SS498; CDC reference strain; from Y. Ike | 25, 40, 116, 117 |
| T2 | ≤1992 | urine |
| Sapporo-603; Sapporo, Japan; from Y. Ike | 25, 40, 116, 117 |
| T3 | ≤1992 | urine |
| Sapporo-109; Sapporo, Japan; from Y. Ike | 25, 40, 116, 117 |
| T4 | ≤1992 | urine |
| Otaru-104; Otaru, Japan; from Y. Ike | 25, 40, 116, 117 |
| T5 | ≤1992 | urine |
| Kobe-16148; Kobe, Japan; from Y. Ike | 25, 40, 116, 117 |
| T6 | ≤1992 | urine |
| Tokyo-74; Tokyo, Japan; from Y. Ike | 25, 40, 116, 117 |
| T7 | ≤1992 | urine |
| Nagasaki-213; Nagasaki, Japan; from Y. Ike | 25, 40, 116, 117 |
| T8 | ≤1992 | urine |
| Nagasaki-742; Nagasaki, Japan; from Y. Ike | 25, 40, 116, 117 |
| T9 | ≤1992 | urine |
| Tokyo-10; Tokyo, Japan; from Y. Ike | 25, 40, 116, 117 |
| T10 | ≤1992 | urine |
| Osaka-34; Osaka, Japan; from Y. Ike | 25, 40, 116, 117 |
| T11 | ≤1992 | urine |
| Sapporo-027; Sapporo, Japan; from Y. Ike | 25, 40, 116, 117 |
| T12 | ≤1992 | urine |
| Okinawa-C1; Okinawa, Japan; from Y. Ike | 25, 40, 116, 117 |
| T13 | ≤1992 | urine |
| Sapporo-6144; Sapporo, Japan; from Y. Ike | 25, 40, 116, 117 |
| T14 | ≤1992 | urine |
| Tokyo-91; Tokyo, Japan; from Y. Ike | 25, 40, 116, 117 |
| T15 | 1973 | wound |
| 1824-73; U.S.; from Y. Ike | 25, 40, 116, 117 |
| T16 | ≤1951 | infant/fecal |
| NCTC8729, s161 type 3; isolated from infant in U.K.; from Y. Ike | 25, 40, 76, 116, 117 |
| T17 | ≤1951 | infant/fecal |
| NCTC8734, B8 type 8; isolated from infant in U.K.; from Y. Ike | 25, 40, 76, 116, 117 |
| T18 | ≤1951 | infant/fecal |
| NCTC 8730, GB122 type 4; isolated from infant in U.K.; from Y. Ike | 25, 40, 76, 116, 117 |
| T19 | ≤1951 | infant/fecal |
| NCTC 8744, D36 type 19; isolated from infant in U.K.; from Y. Ike | 25, 40, 76, 116, 117 |
| T20 | ≤1951 | infant/fecal |
| NCTC 8745, N161 type 20; isolated from infant in U.K.; from Y. Ike | 25, 40, 76, 116, 117 |
| T21 | ≤1951 | infant/fecal |
| NCTC 8731, N83 type 5; isolated from infant in U.K.; from Y. Ike | 25, 40, 76, 116, 117 |
| F1 | early 1900s | milk |
| ATCC 376, L36 | |
| SS-7 | 1918 | cheese |
| Lancefield C1; from R. Facklam | 115 |
| ATCC 4200 | 3/23/1926 | blood |
| R.F.1; rheumatic fever isolate | 119, 120 |
| SS-6 | 1930s | unknown |
| Lancefield D76; from R. Facklam | |
| X98 | 1934 | infant/fecal |
| Lancefield H69D6, ATCC 27276 | 39, 121, 138 |
| ATCC 6055 | ≤1937 | milk |
| In1, NCTC5957 | |
| D173 | 7/16/1939 | blood |
| 18085 (R. Lancefield via V. Fischetti) | |
| ATCC 19433 | ≤1942 | ref strain |
| NCTC775, DSM20478, JCM8726, NCDO581, Tissier strain; control strain for Group D | 128, 130 |
| ATCC 10100 | ≤1948 | ref strain |
| P-60, NCIB7432, NCIB8644; originally from R. Williams as | 134 |
| RMC1 | 2/18/1954 | clinical |
| 54×40; from the collection of Roger M. Cole of the NIAID via D. LeBlanc | |
| RMC5 | 12/14/1954 | clinical |
| 54×518; from the collection of Roger M. Cole of the NIAID via D. LeBlanc | |
| B653 | 4/25/1956 | blood/endo |
| 10D; blood culture of endocarditis patient (R. Lancefield via V. Fischetti) | |
| E1 | 1960s | endocarditis |
| MGH Boston, MA; U.S.; from R. Moellering | 142, 143 |
| RM3817 | 1960s | blood |
| 3817; MGH Boston, MA, U.S.; from R. Moellering | 98 |
| RM4679 | 1960s | blood |
| 4679; MGH Boston, MA, U.S.; from R. Moellering | 98 |
| E1Sol | 1960s | fecal |
| stool surveillance sample from antibiotic-naive population, Solomon Islands | 144 |
| Ned10 | 1961 | horse |
| D5278/61; Netherlands; from R. Willems | |
| ATCC 27275 | ≤1962 | unknown |
| X52 (from P.H. Koppen) | 138 |
| RMC65 | 11/21/1963 | unknown |
| 63×35; from the collection of Roger M. Cole of the NIAID via D. LeBlanc | |
| 39-5 | ≤1964 | oral |
| oral isolate from periodontitis (from Rosan&Williams); contains at least 6 known plasmids; from D. Clewell | 75, 139, 145 |
| FA2-2 | ≤1973 | clinical |
| U.K.; Rif/Fus resistant mutant derived from plasmid-free strain JH2 (Jacob and Hobbs); common laboratory strain | 33, 136 |
| JH1 | ≤1974 | clinical |
| isolated in U.K.; Kan/Strep/Erm/Tet resistant isolate containing multiple plasmids; from D. Clewell; common laboratory strain | 33, 137, 141 |
| DS5 | ≤1974 | unknown |
| FDA strain PCI1326, ATCC 14508, NCDO2131; Erm/Tet resistant isolate containing plasmids α, β, and γ; from D. Clewell | 11, 140 |
| ATCC 29200 | ≤1974 | urogenital |
| 8413; Quebec, Canada; bacteriophage host | 135 |
| OG1RF | ≤1975 | oral |
| ATCC 47077; plasmid-free, Rif/Fus resistant mutant of OG1; common laboratory strain | 42, 43 |
| ATCC 27959 | ≤1975 | cow |
| NADC A-12; bovine mastitis isolate, Iowa, U.S. | 129 |
| 5952 | ≤1976 | clinical |
| Ann Arbor, MI, U.S.; contains plasmids pOB1? from D. Clewell | 72, 75 |
| DS16 | ≤1978 | clinical |
| Ann Arbor, MI, U.S.; contains plasmids pAD1? from D. Clewell; Tet/Erm/Strep/Kan resistant | 9, 74, 136, 146 |
| RC73 | ≤1979 | clinical |
| Ann Arbor, MI, U.S.; contains 5 known plasmids; Tet resistant; from D. Clewell | 75 |
| ATCC 35038 | 1980s | chicken |
| NCTC 11428, F87/268, PB21; intestine of young chicken | 147, 148 |
| HH22 | ≤1982 | urine |
| Houston, TX, U.S.; Erm/Tet/Amp/Gent resistant isolate; first identified β-lactamase producing | 22, 24, 41, 149 |
| A-2-1 | early 1980s | infant/sepsis |
| Denver, CO, U.S.; outbreak of neonatal sepsis (1980-1984), from R. Facklam | 127 |
| A-3-1 | early 1980s | infant/sepsis |
| Denver, CO, U.S.; outbreak of neonatal sepsis (1980-1984), from R. Facklam | 127 |
| B-4-111 | early 1980s | infant/sepsis |
| Denver, CO, U.S.; outbreak of neonatal sepsis (1980-1984); from R. Facklam | 127 |
| SF19 | mid 1980s | clinical |
| Michigan, U.S.; Gent resistant isolate; from M. Zervos | |
| MMH594 | 1985 | blood |
| Wisconsin, U.S.; Erm/Gent resistant; first identified and sequenced pathogenicity island; common laboratory strain | 10, 126 |
| SF100 | mid 1980s | clinical |
| California, U.S. Gent/Strep resistant; from M. Zervos | 150 |
| SF105 | mid 1980s | clinical |
| California, U.S. Gent/Strep resistant; from M. Zervos | 150 |
| SF339 | 1986 | clinical |
| Virginia, U.S.; Gent resistant; contains Tn924; from M. Zervos | 131, 132 |
| SF350 | 1986 | clinical |
| Winnipeg, Canada; Gent resistant; contains Tn924 and multiple plasmids; from M. Zervos | 131, 132 |
| SF370 | 1986 | clinical |
| Cleveland, OH, U.S.; Gent resistant; contains Tn924; from M. Zervos | 131, 132 |
| WH571 | Nov-86 | urine |
| Connecticut, U.S.; Gent/Pen/Cm/Erm/Tet/Kan/ Strep resistant, β-lactamase-producing isolate; from J. Patterson | 122-124, 133 |
| CH19 | Jul-87 | wound |
| Boston, MA; Gent/Pen/Erm/Tet/Strep/Kan resistant, β-lactamase-producing isolate; from L.B. Rice | 118 |
| WH245 | ≤1987 | urine |
| West Haven, Connecticut, U.S.; Cm/Strep/Erm/Tet/Pen resistant, β-lactamase-producing isolate; from J. Patterson | 122, 123, 125, 133 |
| WH257 | ≤1987 | urine |
| West Haven, Connecticut, U.S.; Gent/Strep/Erm/Tet/Pen resistant, β-lactamase-producing isolate; from J. Patterson | 122, 123, 125, 133 |
| CH570 | ≤1987 | blood |
| Canonsburg, PA, U.S.; Gent/Cm/Amp resistant, β−lactamase-producing isolate; from J. Patterson | 122-124, 133 |
| V583 | 2/12/1987 | blood |
| ATCC700802; St. Louis, MO, U.S.; First isolated Vancomycin-resistant and first sequenced | 18, 19 |
| V587 | 2/26/1987 | urine |
| St. Louis, MO, U.S.; Van resistant; (different patient from V583) | 18 |
| CH116 | 1987-1988 | fecal |
| Boston, MA; U.S.; Gent/Kan/Strep/Tet/Erm/Pen resistant, β−lactamase-producing isolate; from L.B. Rice | 118 |
| CH136 | 1987-1988 | urine |
| Boston, MA; U.S.; Gent/Kan/Strep/Tet/Erm/Pen resistant, β−lactamase-producing isolate; from L.B. Rice | 118 |
| CH188 | late 80s | liver |
| Boston, MA; U.S.; Gent/Kan/Strep/Tet/Erm/Cm?/Pen resistant, β-lactamase-producing isolate; from L.B. Rice | 118 |
| SF1592 | late 80s | clinical |
| Delaware, U.S.; β-lactamase-producing isolate; from M. Zervos | |
| SF5039 | 1/1/1991 | urine |
| Michigan, U.S.; Van resistant isolate; from M. Zervos | |
| SF6375 | 10/1/1991 | clinical |
| Michigan, U.S.; Van resistant isolate; from M. Zervos | |
| YI6-1 | ≤1992 | clinical |
| Japan; Tet resistant, plasmid-free derivative of YI6; first isolate characterized with chromosomal-encoded cytolysin; from Y. Ike | 31 |
| TR161 | 10/23/1993 | blood |
| Buffalo, NY, U.S. (Sisters Hospital); from T. Russo | |
| TR197 | 10/30/1993 | blood |
| Buffalo, NY, U.S. (Buffalo Gen. Hosp.); from T. Russo | |
| 599951 | 3/6/1994 | blood |
| Chicago, IL, U.S.; Van resistant; from M. Hayden | |
| SF21520 | mid 1990s | blood |
| Valencia, Spain; Van resistant; from M. Zervos | 151 |
| SF21521 | mid 1990s | blood |
| Valencia, Spain; Van resistant; from M. Zervos | 151 |
| 12030 | mid 1990s | clinical |
| Cleveland, OH, U.S. | 83, 152, 153 |
| 12107 | mid 1990s | clinical |
| Cleveland, OH, U.S. | 83, 152, 153 |
| 79-3 | 10/4/1999 | blood |
| Chicago, IL, U.S.; Van resistant; from M. Hayden | |
| AR01/DG | 8/1/2001 | dog* |
| New Zealand; dog wound isolate; First isolated bacitracin resistant isolate; Van/Erm/Tet resistant; *same as common Van resistant chicken isolates in N.Z.; from J. Manson | 154 |
| SF24396 | 2001 | urine |
| Michigan, U.S.; from M. Zervos | |
| SF24397 | 2001 | urine |
| Michigan, U.S.; from M. Zervos | |
| SF24413 | 2002 | urine |
| Michigan, U.S.; Van resistant isolate; from M. Zervos | 155 |
| SF26630 | 2002 | urine |
| Michigan, U.S.; Van resistant isolate; from M. Zervos | 155 |
| HIP11704 | 2002 | clinical |
| Michigan, U.S.; Van/Erm strain co-isolated from VRSA patient (VanA); from L. Weigel | 142 |
| Merz89 | 7/6/2002 | blood |
| 89; Johns Hopkins Hosp., Maryland, U.S.; | 156 |
| Merz96 | 5/3/2002 | blood |
| 96; Johns Hopkins Hosp., Maryland, U.S.; Van resistant isolate; from W.G. Merz | 156 |
| Merz151 | 12/6/2002 | blood |
| 151; Johns Hopkins Hosp., Maryland, U.S.; Van resistant isolate; from W.G. Merz | 156 |
| Merz192 | 5/5/2002 | blood |
| 192; Johns Hopkins Hosp., Maryland, U.S.; esp+ isolate; from W.G. Merz | 156 |
| Merz204 | 7/11/2002 | blood |
| 204; Johns Hopkins Hosp., Maryland, U.S.; | 156 |
| SF28073 | 2003 | urine |
| Michigan, U.S.; Van resistant isolate; from M. Zervos | 155 |
| Pan7 | 3/5/2005 | commensal |
| Panose 7; fecal sample of healthy volunteer; Boston, MA, U.S. | |
| Fly1 | 7/5/2005 | drosophila |
| commensal isolate of wild-captured fly; Oklahoma, U.S.; isolated by C. Cox | |
| Fly 2 | 2005 | drosophila |
| commensal isolate of Oregon R Bloomington fly stock (immediately upon arrival); isolated by C. Cox | |
| Com1 | 2/1/2006 | commensal |
| fecal sample of healthy volunteer; Boston, MA, U.S. | |
| Com2 | 2/1/2006 | commensal |
| fecal sample of healthy volunteer; Boston, MA, U.S. | |
| Com6 | 2/1/2006 | commensal |
| fecal sample of healthy volunteer; Boston, MA, U.S. | |
| Com7 | 2/1/2006 | commensal |
| fecal sample of healthy volunteer; Boston, MA, U.S. | |
| D1 | unknown | pig |
| 73-30082-2; Denmark; from L.B. Jensen | |
| D3 | unknown | pig |
| 73-30245-2; Denmark; from L.B. Jensen | |
| D6 | unknown | pig |
| 73-30318-4; Denmark; from L.B. Jensen |
Figure 1Dendrogram created from serological typing strains using the E. faecalis MLST database efaecalis.mlst.net.
Multi-locus sequence typing (MLST) of E. faecalis isolates was based on sequences of internal gene fragments for 7 housekeeping genes. Each gene variation (for each of the seven genes) is assigned a unique allele number. The combination of the 7 allele numbers (allelic profile) for each strain defines the multi-locus sequence type, or ST. The relatedness of isolates based on sequence type is shown as an unrooted cladogram, determined by (UPGMA) analysis of the allelic profiles. Boxed isolates represent the most common serotypes found in human populations in previous studies [25], [40].
Figure 2Dendogram of isolates aligned with capsule type, pathogenicity island segments, and antibiotic resistance traits.
MLST-based dendrogram showing genetic relationship of all E. faecalis isolates in this study. Small yellow highlights indicate a serotyping type strain, while black boxes designate the five most common serotypes [40]. Arrows designate isolates used for comparative genomic microarray analysis. Abbreviations are defined as follows: ST = sequence type; CPS = capsule type; PAI = pathogenicity island fragment outlined as letter designations in Fig. S1 (A = nuc1; B = cylB; C = esp; D = hydrolase homolog similar to xylS; E = psaA homolog; F = gls-24 like); A red letter B indicates strains that readily transfer cytolysin via mating; AbR = antibiotic resistance; T = tetracycline resistance; TM = tetM+; TL = tetL+; E = ermB+; VA = vanA+; VB = vanB+; G = gentamicin resistant; C = cat+; A = blaZ+; CBH = bile salt hydrolase; GEL = gelatinase; CYL = cytolysin. More detailed strain information is listed in Table 1.
Bacterial virulence determinants and putative virulence factors examined.
| Bacterial Determinant | Accession no. | Putative function | Reference | Method of detection |
| PAI | ||||
|
| EF0031 | nuclease (homolog) | 10 | PCR, Southern hybridization |
|
| EF0046-48 | cytolysin production | 35 | PCR, Southern hybridization for |
|
| EF0056 | enterococcal surface protein | 10 | PCR, Southern hybridization |
| hydrolase | EF0077 | glycosyl hydrolase ( | 10 | PCR, Southern hybridization |
|
| EF0095 | metal binding protein (homolog) | 157 | PCR, Southern hybridization |
|
| EF0117 | general stress protein | 10, 158 | PCR, Southern hybridization |
|
| EF0040 | bile salt hydrolase | 10 | PCR, Southern hybridization, CBH assay |
| Other | ||||
|
| EF0085-95 | capsular polysaccharide | 44 | PCR, Southern hybridization |
|
| D85393 | gelatinase | 68, 159, 160 | PCR, Southern hybridization, Gelatinase assay |
|
| EF1821 | accessory gene regulator | 68 | PCR |
| Antibiotic resistance | ||||
|
| X56895 | D-Ala-D-Lac ligase / Vancomycin resistance | 52, 54 | PCR, microdilution assay |
|
| L06138 | D-Ala-D-Lac ligase / Vancomycin resistance | 53, 54 | PCR, microdilution assay |
|
| U86375 | adenine methylase/ erythromycin resistance | 55 | PCR, microdilution assay |
|
| X92945 | chloramphenicol acetyl-transferase/ chloramphenicol | 51 | PCR, Southern hybridization, resistance assay |
|
| X92947 | ribosomal protection / tetracycline resistance | 48 | PCR, Southern hybridization, resistance assay |
|
| NC_005013 | efflux pump / tetracycline resistance | 47 | PCR, Southern hybridization, resistance assay |
|
| M13771 | bifunctional enzyme / high-level aminoglycoside resistance | 50 | PCR, Southern hybridization, resistance assay |
|
| M60253 | β-lactamase / β-lactam resistance | 49 | PCR, nitrocefin assay, resistance assay |
Distribution of putative virulence genes in five most common clonal groups.
| clonal group | CC21 | CC9 | CC2 | CC8 | CC40 | non-clustering | Total from groups |
|
| 9 | 12 | 15 | 11 | 14 | 45 | 61 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Groups are comprised of abundant clonal isolates (n>3) and their single and double locus variants as determined by MLST analysis (Fig 3) and eBURST [24]: CC21 = ST21&70, CC9 = ST9&106, CC2 = ST2&6, CC8 = ST8, 64, 90, &112, and CC40 = ST 40&114. Numbers in bold indicate percentage of isolates positive for the specified genotype for a given grouping as calculated from the number of positive versus total isolates in parentheses. Genes investigated above the dashed line encode antibiotic resistance determinants, while those below the dash are known to the pathogenicity island of E. faecalis and/or code for auxiliary enzymes (see Table 2). Antibiotic resistance genotypes encoded by genes other than those listed are not included in this table. * = putative nuclease and glycosyl hydrolase genes
Figure 3Dendrogram and composite virulence determinants among sequence types.
MLST-based dendrogram compiling data from isolates of the 51 identified sequence type lineages. PAI = number pathogenicity island genes present per lineage; AbR = number of antibiotic resistance determinants per lineage. Brackets encompass abundant clonal isolates and their single and double locus variants where applicable.
Figure 4Virulence-associated phenotypes and corresponding genotype for all isolates.
Phenotypes were determined by microdilution assay for antibiotic resistance or enzyme-specific tests for auxiliary enzymatic traits. Genotypes were determined by PCR amplification and/or hybridization for genes known to encode each phenotype. A positive genotype is indicated by the presence of one or more genes known to produce a given phenotype (e.g. genotypically positive vancomycin strains may contain the vanA or vanB genes—a strain containing both would only be counted once).
Figure 5Visualization of final absent and present calls for all probe sets across 8 distinct E. faecalis isolates.
Comparative genomic hybridization was performed on DNA from isolates V583, MMH594, JH1, HIP11704, D6, ARO1/DG, Com6, and Fly1 as described in materials and methods. Probe sets are ordered according to the E. faecalis V583 gene sequence and the Affymetrix library file. Absent probe sets are in white; present probe sets are in black. Clustering of the strains was based on complete linkage using the Pearson correlation coefficient for the Absent/Present calls (A = 0, P = 1). The same clustering pattern is generated when average signal intensity values are used instead of Absent/Present calls (not shown). The numbered regions on the left correspond to the following previously identified and unidentified mobile genetic regions from strain V583: 1) EF_0125-EF_0166, 2) EF_0302-EF_0355 (PHAGE01), 3) EF_0479-EF_0628 (V583 PAI), 4) EF_1275-EF_1293 (PHAGE02), 5) EF_1416-EF_1489 (PHAGE03), 6) EF_1847-EF_1897, 7) EF_1987-EF_2043 (PHAGE04), 8) EF_2084-EF_2145 (PHAGE05), 9) EF_2240-2282/EF_2335-2351, 10) EF_2284-EF_2334 (Tn/vanB), 11) EF_2512-EF_2545, 12) EF_2798-EF_2856 (PHAGE06), and 13) EF_2936-EF_2955 (PHAGE07) (see text).
Present calls for Comparative Genomic Hybridization probe sets by isolate.
| Strain | ARO1/DG | Com6 | Fly1 | JH1 | HIP11704 | D6 | MMH594 | V583 |
| Present calls for V583 chromosome | 2417 | 2422 | 2535 | 2404 | 2615 | 2483 | 3110 | 3256 |
| % present calls for V583 chromosome |
|
|
|
|
|
|
|
|
| Present calls in all bacterial probe sets | 2493 | 2425 | 2566 | 2407 | 2739 | 2559 | 3210 | 3409 |
| % present calls in all bacterial probe sets |
|
|
|
|
|
|
|
|
Figure 6Classification of core and dispensable sequences in 8 strains of Enterococcus faecalis.
Data from comparative genomic hybridization analysis of isolates V583, MMH594, JH1, HIP11704, D6, ARO1/DG, Com6, and Fly1 are organized by the number of strains for which each probe set is detected (top to bottom). Absent probe sets are in white; present probe sets are in black. Clustering of the strains was based on complete linkage using the Pearson correlation coefficient for the Absent/Present calls (A = 0, P = 1). Genetic elements were classified as part of the core genome if present in all strains tested. COG designations were obtained from the National Center for Biotechnology Information (NCBI). Some genes/probe sets represent more than one COG category.
Presence of 6 representative PAI genes compared to total PAI probe sets by comparative genomic hybridization.
| Strain | Com6 | Fly1 | ARO1/DG | JH1 | V583 | HIP11704 | D6 | MMH594 |
| Origin | commensal | insect | dog | clinical | clinical | clinical | pig | clinical |
| Sequence type (ST) | 21 | 101 | 108 | 40 | 6 | 4 | 16 | 6 |
| 6 gene PAI profile | 0/6 | 0/6 | 0/6 | 2/6 | 4/6 | 5/6 | 6/6 | 6/6 |
| CGH PAI probe sets | 0/141 | 0/141 | 3/141 | 56/141 | 125/141 | 111/141 | 138/141 | 137/141 |
6 gene PAI profile includes the nuclease homolog, cylB, esp, xylS homolog, psaA homolog, and gls-24 like genes outlined in Fig S1 and Table 2.
PAI probe sets were designed to the combined V583 and MMH594 PAI sequences (EF_0479-EF_0628 and EF0001-EF0129, respectively) and represent 139 ORFs.
Figure 7Antibiotic determinants and pathogenicity island composition per sequence type lineage, aligned by capsule locus (cps) variation (CPS type).
The percentage of sequence type lineages positive for each antibiotic resistance and pathogenicity island listed in Fig 3 were alligned by CPS capsule type and arranged in descending order. Capsule types are invariant for strains within individual sequence type lineages. Details of capsule operon (cps) arrangements are outlined in Materials and Methods.